Fig 3. Combined inhibition of EGFR and c-Met in c-Met⁺ HCC leads to superior suppression of tumor growth than c-Met inhibitor alone in c-Met⁺ HCC.

XTT cell viability assay 48 hours after treatment of A) MHCC97-H and B) SNU-449 cells treated with EGFR inhibitor gefitinib, c-Met inhibitor PHA665752 or both inhibitors. C) Apoptosis by flow cytometry of MHCC97-H cells treated with EGFR inhibitor gefitinib (10 μM), c-Met inhibitor PHA665752 (1 μM) or both. D) PARP cleavage by immunoblot 48 hours after treatment of MHCC97-H cells with EGFR inhibitor gefitinib (10 μM), c-Met inhibitor PHA665752 (1 μM) or both inhibitors.